EPCAM and breast cancer: Second, we characterized CTC subsets possessing six cell surface expression markers (CD45−/EpCAM-negative/CD44+/CD24−/uPAR+/−/int β1+/−) to determine the expression profiling of candidate genes related to breast cancer and embryonic stem-cell pathways and demonstrate their tumor origin as putative CTCs.